Date/TimeDate(s) - April 24, 2022 - April 27, 2022 All Day
LocationMesse Wien Exhibition and Congress Center
Join NAMSA in Vienna, Austria at the European Conference on Interventional Oncology (ECIO) 2022. Considered the world’s most comprehensive platform for interventional oncology education, this event covers the entire spectrum of treatments interventional oncology can offer to cancer patients, including well-established therapies.
NAMSA EDUCATION SESSION
The Role of Contract Research Organisations in Clinical Trials
Presented by Dr. Jean-Francois Geschwind; Medical Director, Oncology abd Image-Guided Therapy
25 April 2022 | 17:00-18:30 CEST
NAMSA’s MedTech experts will be available on-site for consultations. We welcome the opportunity to discuss the various pathways to market and suggestions on how to most efficiently and cost-effectively achieve market success based on your unique project objectives. Please contact us to reserve your consultation time.
Dr. Jean-Francois GeschwindMedical Director, Oncology and Image-Guided Therapy
Dr. Geschwind earned his Medical Degree from Boston University School of Medicine, completed his residency training in Diagnostic Radiology at the University of California at San Francisco as a Resident-Scholar sponsored by the National Institutes of Health (NIH) and his fellowship training in Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine. He is the former Director of the Division of Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine and Chairman of Radiology and Biomedical Imaging at Yale School of Medicine.
Dr. Geschwind has published almost 300 scientific manuscripts (Google Scholar H-Index 75), wrote the first textbook dedicated to Interventional Oncology, co-edited the textbook of reference in Interventional Radiology, namely, Abram’s Angiography, and was the lead or co-investigator on more than 50 clinical trials testing innovative treatments for patients with liver cancer. Dr. Geschwind is recognized internationally as an expert and key opinion leader in liver cancer, more generally the new field of Interventional Oncology.